ANYO Labs is an early drug discovery company with a novel patent pending artificial intelligence scoring method that addresses the major bottlenecks of speed, accuracy, and lack of novel compounds for difficultly drug-able targets. The methods, stemming from computational and theoretical chemistry research allow for extreme data and energy efficient ways of finding drug compounds for further testing in the lab and clinical trials. The predictive accuracies top 3 different benchmarks in scoring, screening, and ranking power. We have incorporated in december 2022, secured initial funding, have validated our technology through benchmarks, case studies, customer interviews, a pilot project, and worked with customers from academia and biotech companies. The first user cases revealed experimentally validated hits in fractions of the costs in a months time for an infectious disease target. Our current projects focus on inflammatory and oncological targets, and have the capacity to collaborate with small molecular targets outside of these disease areas as well. ANYO Labs now looking into synthesising proprietary compounds for hard to drug targets in neoplasms as well as neglected diseases, and are looking for strategic partners as well as biotech companies willing to try to apply our product in their R&D.